Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors
- PMID: 2910444
- DOI: 10.1002/1097-0142(19890115)63:2<364::aid-cncr2820630228>3.0.co;2-v
Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors
Abstract
Regional recurrence of malignant tumors in the peritoneal cavity usually signifies a poor prognosis for the host and often results in gastrointestinal complications requiring surgical intervention. One hundred patients with nongynecological malignancies found with peritoneal carcinomatosis were followed prospectively. The most common primary tumors were colorectal (N = 45) and pancreatic (N = 20) carcinoma. When associated with pancreatic carcinoma, 65% of patients had liver metastases and 60% had ascites. The presence of ascites was associated with poor survival, with no patient surviving past 30 days. Ascites was also a sign of poor prognosis in patients with colorectal carcinoma. Among possible prognostic factors in colorectal carcinoma patients, only disease-free interval, presence of lung metastases, and ascites showed statistically significant correlations with survival. Peritoneal carcinomatosis in sarcoma (N = 7) and breast cancer (N = 6) patients had median survival of 12 and 7 months, respectively. Surgical intervention for gastrointestinal complications in peritoneal carcinomatosis can provide significant palliation, with a few exceptions such as in patients with pancreatic or gastric carcinoma, ascites, and poor performance status.
Similar articles
-
Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer.Ann Surg Oncol. 2001 Sep;8(8):632-7. doi: 10.1007/s10434-001-0632-1. Ann Surg Oncol. 2001. PMID: 11569777
-
Lymph nodes ratio is associated with the survival of colorectal cancer patients with peritoneal carcinomatosis.Am Surg. 2011 May;77(5):602-7. Am Surg. 2011. PMID: 21679595
-
Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA.Gastrointest Endosc. 2010 Feb;71(2):260-5. doi: 10.1016/j.gie.2009.08.025. Epub 2009 Nov 17. Gastrointest Endosc. 2010. PMID: 19922924
-
Incidence and prognosis of synchronous colorectal carcinomatosis.Future Oncol. 2013 Apr;9(4):541-9. doi: 10.2217/fon.12.206. Future Oncol. 2013. PMID: 23560376 Review.
-
Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin.Dis Colon Rectum. 2013 Dec;56(12):1373-80. doi: 10.1097/DCR.0b013e3182a62d9d. Dis Colon Rectum. 2013. PMID: 24201391 Review.
Cited by
-
Patients at risk for peritoneal surface malignancy of colorectal cancer origin: the role of second look laparotomy.J Cancer. 2013;4(3):262-9. doi: 10.7150/jca.5831. Epub 2013 Mar 15. J Cancer. 2013. PMID: 23459716 Free PMC article.
-
Treatment of malignant peritoneal effusion in digestive and ovarian cancer.Med Oncol Tumor Pharmacother. 1992;9(4):177-81. doi: 10.1007/BF02987754. Med Oncol Tumor Pharmacother. 1992. PMID: 1342062 Clinical Trial.
-
Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy used as treatment of colo-rectal carcinomatosis: a multicentric study.Updates Surg. 2020 Mar;72(1):163-170. doi: 10.1007/s13304-019-00691-8. Epub 2019 Nov 15. Updates Surg. 2020. PMID: 31729630
-
Colorectal Cancer OncoGuia.Clin Transl Oncol. 2010 Mar;12(3):188-210. doi: 10.1007/s12094-010-0489-5. Clin Transl Oncol. 2010. PMID: 20231124 No abstract available.
-
Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.Surg Today. 2006;36(1):57-62. doi: 10.1007/s00595-004-3096-7. Surg Today. 2006. PMID: 16378195
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous